1. Anti‐programmed cell death‐1 therapy in nonmelanoma skin cancer. (17th October 2016) Authors: Winkler, J.K.; Schneiderbauer, R.; Bender, C.; Sedlaczek, O.; Fröhling, S.; Penzel, R.; Enk, A.; Hassel, J.C. Journal: British journal of dermatology Issue: Volume 176:Number 2(2017) Page Start: 498 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Anti‐programmed cell death‐1 therapy in nonmelanoma skin cancer. (1st February 2017) Authors: Winkler, J.K.; Schneiderbauer, R.; Bender, C.; Sedlaczek, O.; Fröhling, S.; Penzel, R.; Enk, A.; Hassel, J.C. Journal: British journal of dermatology Issue: Volume 176:Number 2(2017) Page Start: 498 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Biology-guided precision medicine in rare cancers: Lessons from sarcomas and neuroendocrine tumours. (September 2022) Authors: van der Graaf, W.T.A.; Tesselaar, M.E.T.; McVeigh, T.P.; Oyen, W.J.G.; Fröhling, S. Journal: Seminars in cancer biology Issue: Volume 84(2022) Page Start: 228 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen‐activated protein kinase pathway. (1st March 2022) Authors: Maurus, K.; Kosnopfel, C.; Kneitz, H.; Appenzeller, S.; Schrama, D.; Glutsch, V.; Roth, S.; Gerhard‐Hartmann, E.; Rosenfeldt, M.; Möhrmann, L.; Fröhlich, M.; Hübschmann, D.; Stenzinger, A.; Glimm, H.; Fröhling, S.; Goebeler, M.; Rosenwald, A.; Kutzner, H.; Schilling, B. Journal: British journal of dermatology Issue: Volume 186:Number 3(2022) Page Start: 553 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen‐activated protein kinase pathway. (21st December 2021) Authors: Maurus, K.; Kosnopfel, C.; Kneitz, H.; Appenzeller, S.; Schrama, D.; Glutsch, V.; Roth, S.; Gerhard‐Hartmann, E.; Rosenfeldt, M.; Möhrmann, L.; Fröhlich, M.; Hübschmann, D.; Stenzinger, A.; Glimm, H.; Fröhling, S.; Goebeler, M.; Rosenwald, A.; Kutzner, H.; Schilling, B. Journal: British journal of dermatology Issue: Volume 186:Number 3(2022) Page Start: 553 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma. (18th August 2021) Authors: Westphal, D.; Garzarolli, M.; Sergon, M.; Horak, P.; Hutter, B.; Becker, J.C.; Wiegel, M.; Maczey, E.; Blum, S.; Grosche‐Schlee, S.; Rütten, A.; Ugurel, S.; Stenzinger, A.; Glimm, H.; Aust, D.; Baretton, G.; Beissert, S.; Fröhling, S.; Redler, S.; Surowy, H. Journal: British journal of dermatology Issue: Volume 185:Number 6(2021) Page Start: 1186 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma. (1st December 2021) Authors: Westphal, D.; Garzarolli, M.; Sergon, M.; Horak, P.; Hutter, B.; Becker, J.C.; Wiegel, M.; Maczey, E.; Blum, S.; Grosche‐Schlee, S.; Rütten, A.; Ugurel, S.; Stenzinger, A.; Glimm, H.; Aust, D.; Baretton, G.; Beissert, S.; Fröhling, S.; Redler, S.; Surowy, H. Journal: British journal of dermatology Issue: Volume 185:Number 6(2021) Page Start: 1186 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma. (29th September 2016) Authors: Dieter, S. M.; Heining, C.; Agaimy, A.; Huebschmann, D.; Bonekamp, D.; Hutter, B.; Ehrenberg, K. R.; Fröhlich, M.; Schlesner, M.; Scholl, C.; Schlemmer, H.-P.; Wolf, S.; Mavratzas, A.; Jung, C. S.; Gröschel, S.; von Kalle, C.; Eils, R.; Brors, B.; Penzel, R.; Kriegsmann, M. Journal: Annals of oncology Issue: Volume 28:Number 1(2017) Page Start: 142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. TRANSCRIPTIONAL AND GENOMIC INTRA‐TUMOR HETEROGENEITY DRIVES SUBCLONE SPECIFIC DRUG RESPONSES IN DIFFUSE LARGE B CELL LYMPHOMA. (12th June 2019) Authors: Roider, T.; Frauhammer, F.; Seufert, J.; Bordas, M.; Stolarczyk, M.; Rabe, S.; Malm, J.; Bruch, P.; Hundemer, M.; Rippe, K.; Goeppert, B.; Seiffert, M.; Brors, B.; Mechtersheimer, G.; Müller‐Tidow, C.; Fröhling, S.; Schlesner, M.; Huber, W.; Anders, S.; Dietrich, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗